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Abstract The roles of individual nitric oxide synthases
(NOS) in anthracycline-related cardiotoxicity are not
completely understood. We investigated the effects of a
chronic treatment with doxorubicin (DOX) on knockouts of
the individual NOS isozymes and on transgenic mice with
myocardial overexpression of eNOS. Fractional shortening
(FS) was reduced in untreated homozygous nNOS and
iNOS knockouts as well as in eNOS transgenics. DOX-
induced FS decrease in wild-type mice was attenuated only
in eNOS knockouts, which were found to overexpress
nNOS. No worsening of contractility was observed in
DOX-treated eNOS transgenics and iNOS knockouts.
Although the surviving DOX-treated nNOS knockouts
exhibited no further impairment in contractility, most
(70%) animals died within 7 weeks after treatment onset.
In comparison to untreated wild-type hearts, the nitric oxide
(NO) level was lower in hearts from DOX-treated wild-type
mice and in all three untreated knockouts. DOX treatment
had no effect on NO in the knockouts. These data indicate
differential roles of the individual NOS in DOX-induced
cardiotoxicity. Protection against DOX effects conferred by
eNOS deletion may be mediated by a compensatory
overexpression of nNOS. NOS inhibition-based prevention
of anthracycline-induced cardiotoxicity should be eNOS-




Anthracyclines rank among the most effective antineoplas-
tic drugs (Minotti et al. 2004). An unresolved problem
associated with anthracycline use is the dose-dependent
cardiotoxicity. Years to decades after the chemotherapy, the
cardiotoxicity manifests in 5–20% patients as a congestive
heart failure (CHF) due to dilated cardiomyopathy (van
Dalen et al. 2006). The implementation of cumulative
dosing limits for anthracyclines (e.g., 550 mg/m
2 for
doxorubicin, DOX) following the seminal study by Von
Hoff et al. (1979) did not eliminate cardiotoxicity and CHF.
In addition, limiting cumulative anthracycline dose proba-
bly diminishes the efficacy of the antineoplastic treatments.
Especially problematic is the understandable reluctance of
oncologists to administer anthracyclines to cancer patients
suffering from cardiac co-morbidities and/or those already
treated with anthracycline and requiring further treatment
due to tumor progression or metastases. The co-application
of anthracycline with the only clinically efficacious
cardioprotectant, dexrazoxane, has been limited, due to
weakly evidenced but persisting fears of its negative effect
on anti-tumor efficacy of anthracyclines.
Inhibition of NOS in the heart has been suggested as an
alternative cardioprotective strategy for anthracycline treat-
ments (Fogli et al. 2004). All three NOS isozymes (eNOS,
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Graz, AustriaiNOS, and nNOS) are expressed in mammalian cardiomyo-
cytes. They reduce anthracycline to semiquinone radicals,
which react with oxygen and generate superoxide while
anthracycline is restored (“redox cycling”) (Garner et al.
1999). Superoxide may react with the physiological NOS
product nitric oxide (NO), forming the potent and aggres-
sive cellular oxidant peroxynitrite. The particular sensitivity
of the heart to “oxidative stress” generated in response to
anthracycline has been attributed to the low reactive oxygen
species (ROS) detoxification capacity of cardiomyocytes
(Doroshow et al. 1980).
However, the genetic and pharmacological modulation of
cardiac NOS activity has led to conflicting results. DOX
potentiatedmitochondrialtoxicity(Chaiswingetal.2005)a n d
cardiac injury (Cole et al. 2006) in iNOS knockouts and
induced cardiac iNOS expression in wild-type animals
(Weinstein et al. 2000). This contrasts with a partial
protection against DOX-induced heart damage (although
not against mortality) conferred by iNOS deletion in another
study (Pacher et al. 2003). The disruption of the quantita-
tively dominant cardiac NOS isozyme, eNOS, protected
against DOX-induced heart damage and mortality (Neilan et
al. 2007), whereas the unselective NOS inhibitor nitro-L-
arginine methyl ester (L-NAME) increased mortality associ-
ated with DOX treatment (Pacher et al. 2003). Even more
confusing are the results of biochemical studies: DOX-
induced eNOS transcription accompanied by increased NO
production (Kalivendi et al. 2001) contrasts with eNOS
activation resulting in augmented superoxide and diminished
NO (Vasquez-Vivar et al. 1997) or with NO depletion due to
a direct inhibition of eNOS by DOX (Duquaine et al. 2003).
Opposing effects of anthracyclines on nNOS activity have
been observed in rat brain preparations (Joshi et al. 1996;
Luo and Vincent 1994), whereas the role of this isozyme in
the cardiac response to anthracycline has not been investi-
gated. Some of these discrepancies likely reflect the
considerable analytical challenges associated with cardiac
phenotype, as well as with NO and ROS measurements.
Using NOS knockouts and transgenic mice, we investi-
gated the importance of the individual NOS isozymes to
chronic anthracycline treatment consisting of four low
(3 mg/kg) doses of DOX given over a period of 4 weeks.
Such a dosing resembles typical DOX applications in
humans and may be a better model of DOX-induced
cardiotoxicity than the frequently lethal, single DOX dose
of 20 mg/kg or more applied in most previous experiments
with NOS knockouts (Chaiswing et al. 2005; Cole et al.
2006; Neilan et al. 2007; Pacher et al. 2003). Due to the
complexity of NOS physiology and analytics, we focused
on the clinically relevant parameters of heart failure and on
mortality. The results suggest that cardiac protection against
DOX can be achieved by a specific inhibition of eNOS,
whereas inhibition of nNOS may have a deleterious effect.
Materials and methods
Animals and experimental procedures
Wild-type C57BL/6 J (B6) mice, nNOS (Huang et al. 1993),
iNOS (Laubach et al. 1995), and eNOS (Shesely et al. 1996)
knockouts on the same genetic background were purchased
from Jackson Lab (Bar Harbor, ME, USA). eNOS transgenic
(eNOS-TG) mice overexpressing eNOS exclusively in the
cardiac myocytes were described previously (Brunner et al.
2001). DOX (3 mg/kg) was injected intraperitoneally once a
week over a period of 4 weeks. The treatment was
interrupted for one week between the third and fourth
injection for bone marrow recovery, resulting in a cumulative
dose of 12 mg/kg. The control groups received 0.9% saline
in parallel. Mortality was recorded daily and the experiments
were terminated 4 weeks after the last injection. All of the
experimental procedures conformed to Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health and were approved by the
responsible local ethics committee.
Echocardiography
Four weeks after the last DOX injection, left ventricular
function was assessed in a blinded fashion using in vivo
echocardiography. Animals were lightly anesthetized with
2.5% tribromoethanol (0.01 ml/g) and allowed to breathe
spontaneously. A warming pad was used to maintain
normothermia. 2D-guided M-mode echoes (30 MHz) were
obtained using a VS-VEVO 660/230 High Resolution
Imaging System (VisualSonics, Toronto, Canada). Left
ventricular end diastolic dimension (LVEDD) and left
ventricular end systolic dimension (LVESD) were measured
from original tracings; left ventricular fractional shortening
(FS) was calculated as (LVEDD−LVESD)/LVEDD and
expressed in percent.
High-performance liquid chromatography
At each designated time point, hearts were removed and
homogenized in phosphate-buffered saline (PBS). Daunoru-
bicin was added to the homogenate as the internal standard.
Proteins wereprecipitatedina solutioncontaining ZnSO4 and
methanol by centrifugation at 15,000g for 10 min in a
Biofuge® fresco (Heraeus). One hundred microliters of the
resultant supernatant was transferred into borosilicate glass
autosampler vials for analysis. Calibration curve was con-
structed by adding DOX with known concentrations to
untreated homogenate. High-performance liquid chromatog-
raphy (HPLC) was performed, apart from minor modifica-
tions, as recently described (Kassner et al. 2008), using a
Lichrocart Lichrosphere®-100 RP8e column (Merck, Ger-
26 Naunyn-Schmied Arch Pharmacol (2009) 380:25–34many). The mobile phase was prepared by mixing 25 mM
ammonium acetate buffer (pH 4.6) with acetonitrile
(76:24, V/V). Triethylamine was added to the mixture at
the end concentration of 0.05% (V/V). The fluorescence of
DOX was detected at the excitation wavelength of 485 nm
and emission wavelength of 595 nm.
Taqman assay
ThreedaysafterDOXinjection,totalRNAwasextractedfrom
the left ventricle using the Kit PeqGold RNA pure (Peqlab,
Erlangen, Germany) and reversely transcribed to cDNAwith
the High-Capacity cDNA Reverse Transcription Kits (Ap-
plied Biosystems). Gene expression levels of three NOS
isozymes were measured in triplicate using Taqman assays.
For each reaction, 1µl cDNA resulting from reverse tran-
scriptionof2µgtotalRNAwasmixedwithTaqManUniversal
PCR Master Mix (Applied Biosystems) and an appropriate
TaqMan Gene Expression Assay from Applied Biosystems
(nNOS, Mm00435175_m1; iNOS, Mm00440485_m1;
eNOS, Mm00435204_m1). PCR was performed at recom-
mendedconditionsandmRNAcopynumberswerecalculated
according to standard curves obtained with defined numbers
of plasmids containing subcloned individual NOS cDNAs.
18S ribosomal RNA (Hs99999901_s1, Applied Biosystems)
was determined in the samesamples and the results were used
for normalization of NOS expression.
Western blot
Three days after each injection, three animals from each
group were sacrificed and left ventricles were removed and
homogenized in buffer containing 50 mM Tris (pH 7.4),
150 mM NaCl, 50 mM NaF, 1 mM EGTA, 1 mM EDTA,
40 mM β-glycerophosphate, 10% glycerin, 1% Triton X-
100, and proteinase inhibitors. Proteins (50μg) were
separated by 7.5% SDS-PAGE gel and subsequently
transferred to a PVDF membrane. eNOS isozyme was
probed using mouse monoclonal antibody against eNOS
(BD Bioscience). Proteins containing 3-nitrated tyrosine
were detected with the rabbit anti-mouse polyclonal
antibody against 3-nitrotyrosine (3-NT) (Upstate). β-
Tubulin was detected as loading control using mouse
monoclonal antibody against β-tubulin (Sigma). Expression
of immunoblotted proteins was visualized using an en-
hanced chemiluminescence detection kit (Amersham).
Cardiac NO and malondialdehyde measurement
Cardiac NO and malondialdehyde (MDA) levels were
measured 3 days after each injection. Three mice from
each group were sacrificed by cervical dislocation and
the whole hearts were homogenized in 10% PBS (W/V).
After centrifugation through Vivaspin 500 (10,000 MW
cutoff) filters (Vivascience AG, Hannover, Germany) to
remove the proteins, NO level was assessed in the
supernatant as total nitrate and nitrite using the Nitric
Oxide Assay Kit from Calbiochem (Cat. No. 482655).
MDA level was measured in the supernatants of heart
homogenates (3,000g for 10 min, 4°C.) using the Lipid
Hydroperoxide (LPO) Assay Kit from Calbiochem (Cat.
No. 437634) according to the manufacturer's instructions.
Histological study
After echocardiography, the animals were sacrificed by
cervical dislocation; hearts were excised, fixed in
buffered 4% formaldehyde, embedded in paraffin, and
cut into 5-µm sections. Cardiac collagen deposition was
detected by Azan staining (Liao et al. 2006) according
to standard procedures. Histopathological changes were
examined using a light microscope independently by two
investigators who were blinded regarding the identity of
experimental groups.
Statistical analysis
Results were expressed as mean±SE. Comparisons were
made between groups with one- or two-way ANOVA
followed by post-hoc test. The survival curves were
compared by log rank test. Statistical significance was
defined as P<0.05.
Results
Left ventricular dysfunction and reduced cardiac NO level
in B6 mice following chronic DOX treatment
Only one B6 mouse died in the DOX treatment group
within 60 days after the treatment onset, whereas there
was no mortality in untreated mice (P>0.05, log rank
test, n=10 per group). Left ventricular function was
m o n i t o r e ds e r i a l l y ,2d a y s ,2w e e k s ,4w e e k s ,a n d8w e e k s
after the last DOX injection. FS gradually decreased in
DOX-treated mice from 52% to 31% (P<0.01, n=10 per
group) at 4 weeks after the last injection and remained at
this level for another 4 weeks (Fig. 1a). LVEDD increase,
indicative of dilated cardiomyopathy characteristic for
DOX (Minotti et al. 2004), reached its plateau already
2 weeks after the last DOX injection (Fig. 1b). Therefore,
in all subsequent treatment and genotype groups, echo-
cardiography was conducted 4 weeks after the last DOX
injection.
Cardiac DOX accumulation was determined by HPLC.
After a single dose of 3 mg/kg, DOX was detectable only
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of cardiac DOX accumulation and elimination, B6 mice
were therefore treated with a single injection of 12 mg/kg
DOX and its cardiac accumulation was detected 30 min,
1 h, 6 h, and 24 h after the treatment. We detected no DOX
metabolites at these time points. As shown in Fig. 1c, DOX
level in heart tissues peaked after 1 h and rapidly declined
to <20% of the peak value after 24 h. Therefore, in the
following experiments, NO and MDA levels were mea-
sured 3 days after each injection, i.e., at the projected end of
cardiac DOX elimination. As shown in Fig. 1d, NO level in
hearts from B6 mice decreased after the first DOX injection
and remained unchanged thereafter (n=3 per group). In
contrast, no changes were detected in the marker of
oxidative stress MDA (Fig. 1e, n=3 per group) nor in the
3-nitrotyrosine (not shown) measured in heart homogenates
at the same time points.
Gene expression level of eNOS, iNOS, and nNOS were
measured in untreated B6 animals, as well as after the
second (2 DOX) and the last (4 DOX) injection. eNOS was
the predominant cardiac NOS isozyme in terms of transcript
level, followed by iNOS and nNOS (Fig. 2a, n=4 per
group). Gene expression of nNOS after the last DOX
exposure increased by nearly 50% compared with untreated
mice, reaching a borderline significance (P=0.06). This was
accompanied by a non-significant trend towards lower
levels of eNOS mRNA (Fig. 2a) and a significant one
towards lower eNOS protein expression level (P<0.05,
CON vs. four DOX, Fig. 2b, n=3 per group). Despite
extensive efforts involving various antibodies and experi-
mental conditions, we were unsuccessful in the unequivocal
detection of iNOS and nNOS proteins.
Survival, NO, MDA level, and gene expression in NOS
knockouts and transgenics following chronic DOX
treatment
Out of all treated and untreated eNOS−/−,i N O S −/−, and
eNOS-TG animals, only one DOX-injected eNOS−/−
mouse died within 60 days after the treatment onset
Fig. 1 Model of chronic cardi-
otoxicity employed in this study.
a FS monitored in untreated
(CON) and DOX-treated B6
mice 2 days, 2 weeks, 4 weeks,
or 8 weeks after the last DOX
exposure. #P<0.05, *P<0.01 vs.
CON; n=10 per group. b
LVEDD monitored in B6 mice
at the same time points as in a;
*P<0.01 vs. CON. c DOX was
detected by HPLC in heart tis-
sues from B6 mice 30 min, 1 h,
6 h, and 24 h after a single
injection (12 mg/kg); n=6 per
group. d NO level measured in
heart homogenates from DOX-
treated B6 mice 3 days after
each injection. *P<0.05 vs.
CON; n=3 per group. e MDA
level measured in heart homo-
genates from DOX-treated B6
mice 3 days after each injection;
n=3 per group
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DOX-treated, but none of the untreated, nNOS−/− mice
died within the same time period (P<0.01, log rank test).
The nNOS−/− mice mortality was particularly pronounced
after the last DOX injection (Fig. 3a).
NO level was much lower in heart homogenates of all
NOS knockouts as compared to B6 mice (Fig. 3b, n=3 per
group). A DOX treatment-associated NO decrease was
observed exclusively in B6 mice (Figs. 1d and 3b). Neither
MDA level nor 3-NT changed in any of the knockouts after
DOX exposure (data not shown).
A 2.5-fold overexpression of nNOS gene transcripts was
found in untreated eNOS knockouts compared to untreated
B6 mice (P<0.05, n=4 per group). DOX treatment had no
effect on nNOS gene expression in eNOS−/− mice
(Fig. 3c).
Alterations of cardiac function and histopathology in NOS
knockouts and transgenics following chronic DOX
treatment
Left ventricular function and diameter were evaluated in all
treatment and genotype groups 4 weeks after the last DOX
exposure (Fig. 4, n=3 in DOX-treated nNOS knockouts and
n=6 in other groups). Compared to untreated B6 mice,
untreated iNOS−/−, eNOS-TG, and nNOS−/− mice showed
reduced baseline FS values. Significant changes in FS (a
decrease, Fig. 4a) and LVEDD (an increase, Fig. 4b) upon
DOX treatment were observed exclusively in B6 mice. The
representative images from echocardiography measurements
are displayed in Fig. 4c. In short, untreated eNOS−/− mice
had normal cardiac function and were less sensitive to DOX
treatment compared to B6 mice. The contractility in eNOS-
TG, iNOS−/−, and nNOS−/− mice did not get worse
following DOX exposure.
Cardiac collagen deposition, reflecting heart fibrosis,
was detected in heart sections by histological staining. The
representative micrographs are shown in Fig 5.D O X
treatment resulted in pronounced perivascular fibrosis.
Untreated iNOS or nNOS knockouts showed higher
collagen content compared with untreated B6, without
changes between DOX-treated and -untreated animals
within the same genotype. These observations were
consistent with the functional data obtained from echocar-
diographic measurements.
Discussion
Our data indicate highly differential roles of the individual
NOS isozymes both in normal heart function and following
a chronic DOX treatment. eNOS knockouts exhibit in-
creased contractility in response to ß-adrenergic stimula-
tion, although basal contractility is the same as in wild-type
animals (Mungrue et al. 2002), as also observed in our
study. The reduced FS values in eNOS-TG mice reported
here are consistent with previous observations of dimin-
ished cardiomyocyte contractility in this mouse strain
(Brunner et al. 2001), attributed to chronically elevated
NO generation due to eNOS overexpression (Mungrue et
al. 2002). The reduced FS values in nNOS knockouts are in
agreement with the reduced cardiomyocyte contractility
previously described in this mouse strain in response to ß-
adrenergic stimulation (Barouch et al. 2002). The FS
reduction in untreated iNOS knockouts is more difficult to
explain, since the intracellular localization and physiolog-
ical role of this NOS isozyme in the heart are less well
understood. Although iNOS is frequently and incorrectly
assumed to be expressed in the heart only under patholog-
ical conditions, it has been previously detected in normal
Fig. 2 a Transcript levels of the three NOS isozymes in untreated
(CON) B6 mice as well as 3 days after the second (2 DOX) and fourth
(4 DOX) exposures; n=4 per group. b eNOS protein expression in
heart homogenates from untreated (CON) B6 mice as well as 3 days
after each injection. Positive control: recombinant eNOS protein. ß-
tubulin was used as a loading control. The eNOS signals were
normalized to ß-tubulin and the ratio between them was used to
quantify eNOS protein level
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detection of iNOS mRNA expression in hearts of untreated
wild-type mice, taken together with the presence of a
cardiac phenotype (reduced FS) in iNOS knockouts,
likewise points to a physiological role of iNOS in this
organ. In summary, our data from untreated mice with
altered NOS expression support the growing evidence of
cardiomyocyte contractility undergoing a complex regula-
tion by the individual NOS isozymes. Importantly, NOS-
genotype contractility changes in untreated animals were
not accompanied by heart dilatation, which was observed
only in wild-type mice following DOX treatment.
The expression status of the individual NOS isozymes
had very different effects on heart function in DOX-treated
animals, ranging from protection (eNOS−/−,i N O S −/−,
eNOS-TG) to excessive mortality (nNOS−/−). Although
these differences are valid only for the specified follow-up
period, the present study is one of the longest on the subject
of DOX-induced cardiotoxicity. The protective effect of
iNOS deletion against DOX is in agreement with Pacher et
al. (2003), but in contrast to the results by another group
(Chaiswing et al. 2005; Cole et al. 2006). In contrast to our
work, all these previous studies used much higher sublethal
doses of DOX and very short follow-ups (several days),
which limit both their utility as a model of anthracycline-
induced cardiotoxicity in humans and the comparability to
our results. The lower single DOX doses administered in
our study may explain the absence of iNOS induction in
wild-type mice, in contrast to that of Weinstein et al.
(2000). The same applies to the discrepancy between our
data and the recently reported heart failure and mortality
within days after a single sublethal DOX dose in mice
overexpressing eNOS in cardiomyocytes (Neilan et al.
2007). In our study, a similar eNOS overexpressing mouse
strain (eNOS-TG) shows neither a deterioration of FS
values nor mortality following a chronic DOX treatment. In
contrast, eNOS deletion had a clearly protective effect
against DOX, which was in agreement with the study of
Neilan et al. (2007), whereas the deletion of nNOS was
lethal to most DOX-treated animals. eNOS knockouts
develop hypertension (Mungrue et al. 2002)w h i c h ,
however, did not aggravate the response to DOX. While
extracardiac effects of DOX on nNOS (as well as on all
other) knockouts cannot be excluded, the mice died
suddenly, in the absence of any other signs of sickness.
Nevertheless, additional studies are still required to under-
stand the molecular mechanisms underlying the striking
mortality in nNOS knockouts. Interestingly, increased heart
rate, as described in nNOS knockouts, has been associated
with increased mortality in humans with heart failure
(Mungrue et al. 2002).
Phenotypic differences of this magnitude were unex-
pected, considering the biochemical similarities among the
NOS isozymes in respect of NO production and anthracy-
Fig. 3 The effect of NOS status
on survival and cardiotoxicity.
a Survival curves of DOX-
treated and untreated (CON)
eNOS−/−, iNOS−/−, nNOS−/−.
and eNOS-TG mice. Arrows
indicate the time when DOX
was injected. P<0.05 for
DOX-treated nNOS−/− vs. CON
nNOS−/−, log rank test, n=10
per group. b Cardiac NO levels
measured 3 days after the first
DOX exposure, n=3 per group.
c nNOS transcripts in untreated
B6 and eNOS−/− mice as well
as DOX-treated eNOS−/− mice
3 days after the first, second,
and third DOX exposure, n=4
per group
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suggest that DOX effects may be, at least in part,
independent from NO and ROS. Indeed, despite the very
different effects on heart function and survival, all three
knockouts display similar diminished NO levels, which
remain unaffected by DOX. DOX-induced NO decrease
occurs only in wild-type mice, probably due to inhibition
(Duquaine et al. 2003) rather than decreased expression of
eNOS, since the latter type has a much slower kinetics
(compare Figs. 1ca n d2b). Alternatively, NO effects
relevant to DOX response may take place in subcellular
compartments too small to be detected by methods applied
in our work.
ROS has been suggested to be involved in anthracycline-
induced cardiotoxicity, in part via decreased mRNA and
protein level of manganese superoxide dismutase (MnSOD)
(Li et al. 2000; Li and Singal 2000). Likewise, less
susceptibility to cardiotoxicity has been observed in DOX-
treated MnSOD-overexpressing mice (Cole et al. 2006;Y e n
et al. 1996). We failed to detect enhanced oxidative stress in
wild-type mice following DOX exposure which clearly
results in a deterioration of heart function. Admittedly, this
failure may have resulted from the limited sensitivities of the
methods used or from the relatively late time point of its
assessment. On the other hand, it is in agreement with the
persisting doubts regarding the importance of oxidative
stress in the pathogenesis of anthracycline-induced cardio-
toxicity. Indeed, it has been noted that ROS following
anthracycline exposure is usually detectable only at supra-
clinical or even sublethal anthracycline doses (Gewirtz
1999). Furthermore, most ROS inhibitors or scavengers
failed to prevent anthracycline-induced cardiotoxicity in
clinical trials (van Dalen et al. 2005). The only exception,
the iron chelator dexrazoxane, has been recently suggested to
exert its protective effect on cardiomyocytes via degradation
of the topoisomerase II beta rather than ROS inhibition (Lyu
Fig. 4 Alterations of cardiac function in NOS knockouts and
transgenics following DOX treatment. a FS and b LVEDD values
4 weeks after the last DOX exposure, #P<0.05 vs. untreated (CON)
B6, n=3 in DOX-treated nNOS knockouts and n=6 in other groups. c
Representative images from echocardiography study. SW septal wall
thickness, PW posterior wall thickness
Naunyn-Schmied Arch Pharmacol (2009) 380:25–34 31et al. 2007). Furthermore, eNOS and nNOS disruptions had
very different effects on heart function and survival
following DOX treatment, although both would be expected
to reduce ROS production, consistent with the capability of
all NOS isozymes to redox cycle anthracycline (Garner et al.
1999).
Instead, the protective effect of eNOS deletion against
DOX may be primarily related to the overexpression of
nNOS found in this study in hearts of eNOS knockouts.
nNOS overexpression has previously been reported in other
organs of eNOS−/− mice (Sanz et al. 2001) and may
represent a compensatory response. The gradual decrease in
eNOS expression found here in DOX-treated wild-type
animals may represent a protective response against DOX,
which remains insufficient, since it is not accompanied by
significant changes in nNOS expression. Conversely, nNOS
downregulation or deletion would be expected to be
harmful, which is, indeed, the case. In short, the protective
effect of eNOS deletion against DOX may be mediated by
compensatory overexpression of nNOS. Accordingly,
nNOS would be a downstream effector of eNOS, indis-
pensable to protection against DOX, as evidenced by the
high mortality in nNOS−/− mice. An indispensable and
dominant role of nNOS downstream of eNOS has been
postulated for the beta-adrenergic response, based on
phenotypical similarities of nNOS and double eNOS/nNOS
knockouts (Barouch et al. 2002). The disparate, protective,
and harmful effects of nNOS and eNOS deletions are
reminiscent of their opposing effects on cardiomyocyte
contractility, which are mediated by calcium. Disturbances
of calcium homeostasis have been implicated in
anthracycline-induced cardiotoxicity (Gewirtz 1999). Alto-
gether, the disparate cardiac effects of the individual NOS
may be related to disturbances in the subcellular calcium
homeostasis rather than to NO or ROS. Additionally, as
nNOS has been reported to regulate blood flow (Talman
and Nitschke Dragon 2007), the compensatory increase of
nNOS in eNOS−/− mice may have led to coronary
vasodilation and improved cardiac microcirculation, thus
contributing to the protective effect against DOX-induced
cardiotoxicity.
Taken together, the phenotypes of DOX-treated eNOS
and nNOS knockouts suggest an explanation for the lethal
effect of the unselective NOS inhibitor L-NAME, when
given to mice together with DOX (Pacher et al. 2003). It
appears likely that this lethality was caused by the
inhibition of the indispensable function of nNOS discussed
above. Even more importantly, inhibition of nNOS may
have been responsible for the similarly unexplained reduced
cardiac output, heart failure, and increased mortality in
sepsis patients treated with another unspecific NOS
inhibitor, L-NMMA (Lopez et al. 2004).
In agreement with Neilan et al. (2007), our data suggest
that any NOS modulation-based prevention of anthracycline-
induced cardiotoxicity should aim at a maximally specific
inhibition of eNOS. Selective nNOS upregulation may be an
alternative, but this remains to be demonstrated using an
appropriate mouse model. Most critical is the avoidance of
nNOS inhibition, which is associated with the increased
mortality in our study and may have increased mortality in
previous clinical (Lopez et al. 2004) and animal (Pacher et
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